Scarica l'app Stockscreener
16.33
3.88%
0.61
Dopo l'orario di chiusura:
16.29
-0.04
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$15.72
Aprire:
$15.87
Volume 24 ore:
2.97M
Relative Volume:
1.14
Capitalizzazione di mercato:
$12.66B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-11.30
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
+8.07%
1M Prestazione:
+7.08%
6M Prestazione:
-7.24%
1 anno Prestazione:
-9.23%
Intervallo 1D:
$15.87
$16.64
Intervallo di 1 settimana:
$14.60
$16.64
Portata 52W:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.33 | 12.19B | 220.00K | -1.08B | -326.53M | -1.4448 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.17 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.03 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
742.79 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.38 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
305.39 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Earnings Recap: How correlated is Summit Therapeutics Inc to the S P5002026 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Movement Recap: Is Summit Therapeutics Inc impacted by rising rates2025 Pullback Review & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Gains Market Visibility On Nasdaq Today - Kalkine Media
Aug Outlook: Can Summit Therapeutics Inc stock outperform in a bear marketDollar Strength & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing - simplywall.st
Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Finviz
10 Stocks With Explosive Growth Potential - Insider Monkey
Summit Therapeutics at TD Cowen Conference: Strategic Focus on Ivonesimab - Investing.com
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics Inc. (SMMT) Stock Analysis: Biotech Innovator with an 89.92% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab - Insider Monkey
The Technical Signals Behind (SMMT) That Institutions Follow - Stock Traders Daily
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Q1 EPS Estimate for Summit Therapeutics Increased by Analyst - MarketBeat
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics to Present at Upcoming Investor Conferences - The Chronicle-Journal
Wells Fargo Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
How Summit’s Deeper 2025 Loss and Ivonescimab’s FDA Path At Summit Therapeutics (SMMT) Has Changed Its Investment Story - simplywall.st
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty - Investing.com Australia
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Summit Therapeutics (SMMT) and Intuitive Surgical (ISRG) - The Globe and Mail
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: - GuruFocus
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q4 2025 Earnings Conference - 富途牛牛
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | - GuruFocus
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Finviz
Traders Purchase High Volume of Put Options on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
HC Wainwright Has Lowered Expectations for Summit Therapeutics (NASDAQ:SMMT) Stock Price - MarketBeat
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Q4 Earnings Miss Expectations - GuruFocus
Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus
Summit Therapeutics (SMMT) Highlights Progress in Cancer Drug De - GuruFocus
Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf RegistrationHas The Bull Case Changed? - Yahoo Finance
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss - Investing.com Nigeria
Summit Therapeutics Q4 Earnings Call Highlights - MarketBeat
Summit Therapeutics (SMMT) Updates on HARMONi-3 Trial Progress - GuruFocus
Summit Therapeutics falls on earnings miss despite progress By Investing.com - Investing.com South Africa
Summit Therapeutics falls on earnings miss despite progress - Investing.com
Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks
Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise - marketscreener.com
Summit Therapeutics Inc. SEC 10-K Report - TradingView
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.28%
17.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):